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ARTICLE
Managing clinically significant findings in research:
the UK10K example
Jane Kaye*,1, Matthew Hurles2, Heather Griffin1, Jasote Grewal3, Martin Bobrow4, Nic Timpson5,
Carol Smee2, Patrick Bolton6, Richard Durbin2, Stephanie Dyke2, David Fitzpatrick7, Karen Kennedy2,
Alastair Kent8, Dawn Muddyman2, Francesco Muntoni9, Lucy F Raymond4, Robert Semple4, Tim Spector10
and UK10K11
Recent advances in sequencing technology allow data on the human genome to be generated more quickly and in greater detail
than ever before. Such detail includes findings that may be of significance to the health of the research participant involved.
Although research studies generally do not feed back information on clinically significant findings (CSFs) to participants, this
stance is increasingly being questioned. There may be difficulties and risks in feeding clinically significant information back to
research participants, however, the UK10K consortium sought to address these by creating a detailed management pathway.
This was not intended to create any obligation upon the researchers to feed back any CSFs they discovered. Instead, it provides
a mechanism to ensure that any such findings can be passed on to the participant where appropriate. This paper describes
this mechanism and the specific criteria, which must be fulfilled in order for a finding and participant to qualify for feedback.
This mechanism could be used by future research consortia, and may also assist in the development of sound principles for
dealing with CSFs.
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INTRODUCTION
Advances in sequencing technology are enabling the rapid generation
of information on the whole genome of individuals at an ever
decreasing cost. The possibility of identifying clinically significant
findings (CSFs) – findings that have potential health or reproductive
significance for the individual participant – is greatly increased when
whole-genome information is generated.1 This increase, coupled with
our increased understanding of the relationships between genotype
and phenotype, has created a more pressing debate about the release
of individual results to research participants. Although there is still
considerable diversity of opinion, there is a growing consensus in the
bioethics community that, in some contexts, it would be ethical to
report back CSFs where they could be of benefit to the participant.2,3
A recent report by the American College of Medical Genetics and
Genomics recommended the feedback of a given list of certain
variations within the context of clinical genetic testing, but
explicitly excluded research studies from their recommendations.4
In addition, recent studies have shown that research participants in
the United Kingdom and elsewhere5–7 would like to be informed of
CSFs made in the course of research.8 As yet, there is no widely
accepted agreement on what governance procedures should look like
within genomic research, although a number of models have been
proposed9–12 and exist outside of the United Kingdom.13
The UK10K project management framework has been used to
feedback CSFs where the research participants involved are
recruited either for study of disease, or for general research,
without specific disease-related questions to answer. Within this
management framework, CSFs are broken down into two cate-
gories. These are ‘pertinent findings’ (PFs), which relate to the
disease under investigation in a particular study within the UK10K
project and ‘incidental findings’ (IFs).14 IFs relate to discoveries
outside of the original research objectives of the particular study
for which that subject was recruited into UK10K, and were
unforeseen at the point at which the participant consented to
take part. Researchers in the UK10K study have no obligation to
pass IFs on to participants in the study. The reasons for not doing
so are because (i) the data quality and inference (predictive ability)
is low, (ii) there is a need to verify all findings before action, (iii) it
is not possible to really give informed consent for IFs and (iv) the
costs and resources involved in providing genetic counselling if all
potential IFs were followed up. The UK10K model provides a
mechanism for allowing CSFs from PFs to be reported back to
patients in a responsible manner within the lifetime of the UK10K
project. If a researcher identifies a CSF, the UK10K model allows
them to pass their finding on, so that they can be used for clinical
care following an established governance framework.
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This management pathway was developed by the Ethics Advisory
Group (EAG) in consultation with other members of the project and
is further outlined in a policy document.15 The EAG was formed at
the commencement of the project to address any ethical issues that
were likely to arise, and included researchers, clinicians, bioethics and
legal experts, and patient and cohort participant representatives. The
purpose of this paper is to describe the UK10K management
framework so that it may assist other projects, which may face
similar issues and in doing so further the policy debate about how
best to deal with CSFs in genomics research.
THE UK10K PROJECT
The UK10K project (2010–2013), funded by a Wellcome Trust
Strategic Award, has analysed the DNA ofB10 000 people to improve
the understanding of the role of low-frequency and rare genetic
variants in health and disease.14 Four thousand participants were
drawn from two cohort studies in the UK – TwinsUK and the Avon
Longitudinal Study of Parents and Children (ALSPAC), with the
remaining 6000 samples being taken from participants in 11 different
condition or disease-specific studies. Samples were from the following
three sample groups: neurodevelopment (schizophrenia, bipolar,
autism (Tampere and Atypical), learning disabilities, Asperger
syndrome; obesity; rare diseases (neuromuscular; ocular coloboma;
congenital heart disease; ciliopathies disorders; severe intellectual
disabilities; congenital hypothyroidism; resistance to thyroid
hormone; familial hypercholesterolemia). Many of these participants
have an on-going relationship with the recruiting researchers. Where
conditions relating to data type and participant standpoint/
motivation are appropriate (usually where research participants are
also patients and therefore are likely to benefit directly from the
anticipated findings of the study) a system of informed consent and
information feedback developed along existing lines of clinical
interaction has been put in place and will be discussed below.
The sequencing for the UK10K project was largely carried out
through the Wellcome Trust Sanger Institute. Four thousand of the
participants (TwinsUK and ALSPAC cohorts) were sequenced to
approximately sixfold coverage of their entire genome, to provide a
detailed sequence reference database connected to phenotypic and
clinical data.14 As these are unselected participants for the purposes of
the study, they do not have an ongoing clinical relationship with any
of the researchers in the study, but they do have an ongoing
relationship with the custodians of the cohorts. The framework
below will therefore primarily relate to the 6000 participants from
the disease-specific studies, but not to those from the TwinsUK and
ALSPAC cohorts, where different policies apply. For TwinsUK, there is
a longstanding policy of returning clinical or laboratory results to the
participants and their general practitioners that would be of clinical
use to the local doctor in management decisions. Consent and ethical
approval for the UK10K study was given on the basis that TwinUK
participants would not be provided with the results of the genotypes
or sequence variants other than for determining twin status. For
genetic data of the type collected within the UK10K project, ALSPAC
operate (according to their process of informed consent) a policy of
non-disclosure relating to personal data and research findings.
Participants are asked explicitly for their agreement to the type of
data being collected and to this mode of management. All research
findings are communicated only at the level of the population
through conventional routes of dissemination.
Sequencing of exomes belonging to the 6000 participants from the
disease-specific cohorts to approximately 60 times coverage was
expected to identify roughly 20 000 gene variants in each genome.14
These participants have medical conditions with a likely underlying
monogenic cause and have already consented to genetic research. The
aim of the sequencing was to distinguish those genetic variants that
may be linked to a particular disease and those having no discernible
effect.14 This comprehensive analysis of the protein-coding sequences
within their genomes, coupled with findings obtained from the first
group (TWINS and ALSPAC cohorts), enables the identification of
potential causative genetic mutations in the particular diseases
observed.14 This comprehensive sequencing also raised the
possibility of IFs for this group of participants, but as it was carried
out in a research setting these CSFs were not of a clinical diagnostic
standard.
The reference data set created by the UK10K project is accessible by
the wider research community via the European Genome-Phenome
Archive (EGA) through a managed-access mechanism. This raises
the possibility of researchers outside UK10K also identifying CSFs in the
data to which they have been granted access. This raises the additional
question of how far the procedure for returning CSFs should extend.
Given the range of expertise and specialisms of those external
researchers who might wish to access the data from UK10K, the
possibility that they would identify further CSFs was very real. The
management pathway for handling findings and potential feedback in
the case of PFs was not to impose an obligation on third-party
researchers, but merely to provide a guiding mechanism to deal with
such an eventuality in a responsible manner should it arise. This
management framework will only be effective during the lifetime of
the project, however, it has been suggested that this approach, or the
strategy developed, may be of use to the wider research community.
This is of particular relevance in relation to the public release of
UK10K data and thus the possibility of researchers outside the project
(or study custodians) also identifying CSFs in the data to which they
have been granted access.
THE UK10K MANAGEMENT FRAMEWORK
The purpose of this management framework is to keep clear the
distinction between clinical and research activities and the ensuing
obligations to participants, while at the same time allowing the
possibility for CSFs to be reported back to patients in a responsible
manner where appropriate. When a researcher encounters a CSF, the
management framework can be activated. The clinician with a pre-
existing relationship with the particular research participant has a key
role in the feedback process. Given the large and far-reaching scope of
this project, there are four conditions, which must be met in order for
the framework to be activated. Only if all of these criteria are met, can
the PF or IF be passed on to the participant. These are as follows:
1. To respect the research participant’s right to know or, alternatively,
their right not to know about CSFs. Explicit consent must have
always been given by the participant for IFs and/or PFs to be
returned.
2. CSFs should only be returned where they are of significant clinical
importance.
3. CSFs should be clinically and analytically validated before being
returned to participants by their treating clinician, via a genetically
accredited laboratory.
4. Feedback to individual participants should be conducted by a
trained professional able to provide genetic counselling.
If one or more of these criteria are absent, information on the CSF
will not be fed back to the participant. These are therefore of crucial
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importance and must be considered before the participant is
contacted.
The UK10K management framework comprises four different
stages, from the discovery of a CSF to the return of that finding to
the participant. Although the treating clinician has a central role and
retains ultimate responsibility for communicating any CSFs to the
participant, the particular pathway taken to arrive at this point will
depend on the circumstances and whether the person who identifies
the CSF is within the UK10K project, or outside of it. Figure 1 below
illustrates the four stages within the management framework, and the
specific pathways to be taken by researchers in UK10K. It also details
the pathway for non-UK10K secondary researchers if they wish to
inform the project upon discovering a CSF.
Different pathways
Discovery. There are three types of researcher who might discover
CSFs in the UK10K data:
1. Treating clinicians are UK10K clinical researchers who have an
ongoing clinical role in relation to that participant. They may have
recruited participants into the study and may be the sample
custodian for previously collected samples or those collected
within the lifetime of the project.
2. UK10K researchers who carry no clinical role in relation to the
participant in question, which may include clinician scientists; and
3. Secondary researchers accessing UK10K data through the EGA.
One of the fundamental principles in developing this framework
was that CSFs could only be returned by the clinician who has a pre-
existing relationship with the participant. As a result, they are a key
player within the mechanism. Responsibility lies with the treating
clinician in liaising with participants, and determining whether any
findings should be reported back to them. They also determine
whether it would be feasible to report back CSFs. All consent forms
and management pathways for feeding back CSFs are approved by a
research ethics committee. All UK10K researchers should share PFs
with other UK10K researchers as part of that research collaboration,
but the participant will not necessarily receive this information.
Secondary researchers are those who have accessed UK10K data in the
EGA via the managed data access mechanisms for their own
independent research, and have no role in the feedback process once
they have informed the project of their finding.
Initial contact. On discovery of a CSF, the management pathway for
each type of researcher is as follows:
1. If the CSF is identified by a UK10K researcher, they should first
contact the relevant Sample Custodian (who may also be the
treating clinician) or the UK10K Management Committee. The
UK10K project Management Committee can then ensure that
findings are passed on to the relevant treating clinician responsible
for that participant, and the management framework is activated.
2. If a secondary researcher decides to activate the management
framework, they should contact the UK10K Management Com-
mittee or the Data Access Committee, who will then pass the
findings on to the relevant Sample Custodian who can then pass it
on to the treating clinician.
The treating clinician must first determine whether the participant
has explicitly consented to the feedback of the specific class of finding
(whether pertinent or incidental) by referring to the original consent
form. Difficulties may arise if the clinician is no longer treating the
participant, or the participant has stopped attending the clinic.
Validation. Once it has been established that the participant has
consented to feedback, the next stage of the pathway is activated. The
validation stage within the framework provides for safeguards that
ensure that the original research finding is verified, both clinically and
analytically.14
Figure 1 Depiction of the UK10K Management Framework, consisting of four stages.
CSFs in research
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The analytical validity of the research finding must be established
by a CPA (Clinical Pathology Accreditation) laboratory, which will
confirm the genetic variant in the particular participant. Findings are
validated either by obtaining a fresh independent sample from the
participant, or by using a pre-existing one (provided that it has solely
been handled within a CPA setting) to confirm accuracy.14 However,
before this, it is recommended that findings should be verified by the
treating clinician in an additional experiment (for example, Sanger
sequencing) in order to reduce the workload for the CPA laboratory.
Appropriately qualified experts work with the clinical researcher to
assess the clinical utility and also the validity of the finding by
evaluating the accuracy of the genetic variant in identifying or
predicting the particular disease. Findings must be of significant
clinical importance to the participant. Here a balancing act is carried
out between the risks and the benefits of reporting back, given that
there is always the danger of causing unnecessary harm to participants
and their families by communicating findings. The benefit of
informing participants of CSFs should considerably outweigh any
potential harm that could be caused by reporting back.14
Feedback. Once the CSF has been validated, the treating clinician
will then be able to feedback results to the individual participant if
this is considered appropriate. Feedback will occur in the way the
treating clinician considers most suitable. Given that the studies are all
genetic in nature, the necessary expertise and protocols should be
established to assist in reporting back. Final feedback therefore occurs
via the original clinic, which obtained the initial samples from the
participant. Where, on the other hand, the treating clinician decides
in light of all the evidence (such as whether consent has been
obtained) that it is not appropriate to feedback any CSFs and can
justify this decision, the participant will not be informed.
The decision whether or not to feedback PFs and/or IFs for a given
patient collection was taken by each Sample Custodian in consultation
with their Research Ethics Committee, in light of the four key
requirements for (i) explicit consent, (ii) significant clinical impor-
tance, (iii) analytical and clinical validity and (iv) the availability of an
appropriate feedback mechanism, that were identified by the Ethical
Advisory Group and were universally adopted across the UK10K
project. The result of these deliberations was that none of the Sample
Custodians undertook to feedback IFs, but almost all undertook to
feedback PFs.
THE LIFESPAN OF THE FRAMEWORK
The UK10K management framework was designed not only to
provide a mechanism for dealing with CSFs discovered during the
UK10K project, but it is hoped it will also provide a possible
precedent that might be used in other projects. It provides for an
effective flow of communication between researchers involved in the
same research project but with different expertise based in different
institutions. Information, that is relevant to both researchers and
participants, is relayed from one researcher to another traversing the
different stages, creating a cohesive framework, which ultimately
allows for validated and clinically significant information to be
returned, when appropriate and in a responsible way, to the
participant in a clinical setting.
However, these stages of validation and assessment will not be
possible to sustain once the UK10K project itself comes to an end. It
is therefore intended that once the UK10K project is complete, the
management framework will also come to an end. By this time, data
will have been stored in the EGA and will remain accessible to
researchers involved in other projects. Should these secondary
researchers make any CSFs after the UK10K project has ended, it
will no longer be possible for these to be passed on the UK10K
Management Committee, as this will no longer exist. However, it
might be possible for an appropriately constituted Data Access
Committee to take on this role beyond the life-time of UK10K.
Developing a governance mechanism for the management framework
to be in place in the longer term needs further consideration by policy
makers and funders, particularly as many sample collections will be
continued to be studied after the UK10K project is completed.
CONCLUSION
The UK10K framework addresses the principal ethical concerns when
feeding back CSFs under specific conditions. Sample Custodians are
obliged to pass on CSFs to the treating clinicians, who in turn
are responsible for passing on CSFs to their patients where they meet
the relevant criteria. It also ensures that those with no clinical role are
not responsible for passing on any CSF they may find. It does, however,
ensure that the procedure is there, should a CSF be identified.
Assuming all of the criteria for feedback are met, the finding will pass
through the management framework and the participant will be
informed where appropriate. This may result in them receiving
treatment, which may otherwise not have been prescribed.
However, it must be borne in mind that this approach does not
address the important issue of IFs in population-based collections
(where the issues of truly informed consent, and the provision of
counselling remain poorly addressed as well as sequence data being of
variable predictive capacity) and of course is a model likely to evolve
and may need to be amended in response to changing circumstances.
In the meantime, this framework brings us one step closer to bridging
the gap between research and clinical care. The model has been tested
with regards to PFs, where patients were informed before the first
papers describing novel causal genes for rare diseases were published.
The UK10K model establishes an important precedent for the
feedback of CSFs in genetic and genomic research. It provides the
foundation for a reflexive and responsive framework that will be able
to address further logistical, ethical and legal issues as and when they
come to light.
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